Key result
Cardioprotective therapies affect CMR-assessed edema-based area at risk following reperfused STEMI.
Why the study?
A recent preclinical study showed that the edema-based area at risk is affected by certain cardioprotective therapies used to reduce myocardial infarction size following STEMI.
Answers are grounded in this paper and cite their sources.
Edema-based AAR may be unreliable for CMR assessment of cardioprotective therapies; leaves open translation of preclinical effects to clinical trials.
Cardiovascular magnetic resonance (CMR) has been used to assess the efficacy of novel cardioprotective therapies for reducing myocardial infarction (MI) size following ST-segment elevation MI. A recent preclinical study showed that the edema-based area at risk (AAR) is affected by certain
No takes yet. Share an insight, caveat, or question.
Bulluck et al. (2018) studied this question. Cardioprotective therapies affect the edema-based area at risk assessed by cardiovascular magnetic resonance following reperfused ST-segment elevation myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: